"Leukemia L1210" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An experimental LYMPHOCYTIC LEUKEMIA of mice.
| Descriptor ID |
D007939
|
| MeSH Number(s) |
C04.557.337.372.594 C04.619.531.594
|
| Concept/Terms |
Leukemia L1210- Leukemia L1210
- L1210, Leukemia
- Leukemia L 1210
- L 1210, Leukemia
|
Below are MeSH descriptors whose meaning is more general than "Leukemia L1210".
Below are MeSH descriptors whose meaning is more specific than "Leukemia L1210".
This graph shows the total number of publications written about "Leukemia L1210" by people in this website by year, and whether "Leukemia L1210" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leukemia L1210" by people in Profiles.
-
Liu T, Singh R, Rios Z, Bhushan A, Li M, Sheridan PP, Bearden SE, Lai JCK, Agbenowu S, Cao S, Daniels CK. Tyrosine phosphorylation of HSC70 and its interaction with RFC mediates methotrexate resistance in murine L1210 leukemia cells. Cancer Lett. 2015 Feb 01; 357(1):231-241.
-
Liu T, Dean A, Ashwini S, Sheridan PP, Bhushan A, Lai JC, Cao S, Daniels CK. Identification and characterization of a 66-68-kDa protein as a methotrexate-binding protein in murine leukemia L1210 cells. Cell Stress Chaperones. 2013 Mar; 18(2):223-34.
-
Das S, Das U, Selvakumar P, Sharma RK, Balzarini J, De Clercq E, Moln?r J, Serly J, Bar?th Z, Schatte G, Bandy B, Gorecki DK, Dimmock JR. 3,5-Bis(benzylidene)-4-oxo-1-phosphonopiperidines and related diethyl esters: Potent cytotoxins with multi-drug-resistance reverting properties. ChemMedChem. 2009 Nov; 4(11):1831-40.
-
Capizzi RL. Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside. Invest New Drugs. 1996; 14(3):249-56.
-
Dicker AP, Waltham MC, Volkenandt M, Schweitzer BI, Otter GM, Schmid FA, Sirotnak FM, Bertino JR. Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation. Proc Natl Acad Sci U S A. 1993 Dec 15; 90(24):11797-801.
-
Chandrasekaran B, Kute TE, Capizzi RL. Deoxypyrimidine-induced inhibition of the cytokinetic effects of 1-beta-D-arabinofuranosyluracil. Cancer Chemother Pharmacol. 1992; 29(6):455-60.
-
Rustum YM, Trave F, Zakrzewski SF, Petrelli N, Herrera L, Mittelman A, Arbuck SG, Creaven PJ. Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monogr. 1987; (5):165-70.
-
Lindqvist C, Shapiro IM, Wigzell H. Induction of concanavalin A dose-dependent T-cell growth factor production by insertion of T-cell membrane components into the AKR thymic lymphoma BW 5147. Scand J Immunol. 1986 Jan; 23(1):119-25.
-
Capizzi RL, Cheng YC. Sequential high-dose cytosine arabinoside and asparaginase in refractory acute leukemia. Med Pediatr Oncol. 1982; 10 Suppl 1:221-8.
-
Berd D, Mastrangelo MJ. Differential sensitivity of two murine leukaemia sublines to cytolysis by Corynebacterium parvum-activated macrophages. Br J Cancer. 1981 Dec; 44(6):819-27.